A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design (vol 4, pg 39, 2012)

被引：0
|
作者：
Boyer, T. D.
Medicis, J. J.
Pappas, S. C.
Potenziano, J.
Jamil, K.
机构：
来源：
OPEN ACCESS JOURNAL OF CLINICAL TRIALS | 2012年 / 4卷
关键词：
D O I：
10.2147/OAJCT.S36089
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [1] A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design
    Boyer, Thomas D.
    Medicis, Joseph J.
    Pappas, Stephen Chris
    Potenziano, Jim
    Jamil, Khuramm
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2012, 4 : 39 - 49
  • [2] A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Sanyal, Arun J.
    Boyer, Thomas
    Garcia-Tsao, Guadalupe
    Regenstein, Frederick
    Rossaro, Lorenzo
    Appenrodt, Beate
    Blei, Andres
    Guelberg, Veit
    Sigal, Samuel
    Teuber, Peter
    GASTROENTEROLOGY, 2008, 134 (05) : 1360 - 1368
  • [3] A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)
    Sanyal, Arun
    Boyer, Thomas
    Garcia-Tsao, Guadalupe
    Regenstein, Frederick
    Rossaro, Lorenzo
    Teuber, Peter
    HEPATOLOGY, 2006, 44 (04) : 694A - 694A
  • [4] Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 HRS enrolled in a randomized, double-blind, placebo-controlled trial
    Sanyal, Arun J.
    Boyer, Thomas D.
    Teuber, Peter
    HEPATOLOGY, 2007, 46 (04) : 564A - 564A
  • [5] Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study
    Pomier-Layrargues, G
    Paquin, SC
    Hassoun, Z
    Lafortune, M
    Tran, A
    HEPATOLOGY, 2003, 38 (01) : 238 - 243
  • [6] Initial Report of a Large, Randomized, Double Blind, Placebo-controlled, Phase 3 Trial of Terlipressin plus Albumin for the Treatment of Type 1Hepatorenal Syndrome (HRS-1): The REVERSE Study
    Boyer, Thomas D.
    Sanyal, Arun J.
    Wong, Florence
    Frederick, R. Todd
    Lake, John R.
    O'Leary, Jacqueline G.
    Ganger, Daniel
    Box, Terry D.
    Jamil, Khurram
    Pappas, Stephen Chris
    HEPATOLOGY, 2014, 60 : 255A - 255A
  • [7] A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia: A Preliminary Study (vol 32, pg 593, 2012)
    Niitsu, T.
    Fujisaki, M.
    Shiina, A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (01) : 54 - 54
  • [8] Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kawut, Steven M.
    Ellenberg, Susan S.
    Krowka, Michael J.
    Goldberg, David
    Vargas, Hugo
    Koch, David
    Sharkoski, Tiffany
    Al-Naamani, Nadine
    Fox, Alyson
    Brown, Robert
    Levitsky, Joshua
    Oh, Jae K.
    Lin, Grace
    Song, Nianfu
    Mottram, Carl
    Doyle, Margaret F.
    Kaplan, David E.
    Gupta, Samir
    Fallon, Michael B.
    LIVER TRANSPLANTATION, 2019, 25 (08) : 1155 - 1164
  • [9] Mexiletine in Myotonic Dystrophy Type 1 A Randomized, Double-Blind, Placebo-Controlled Trial
    Heatwole, Chad
    Luebbe, Elizabeth
    Rosero, Spencer
    Eichinger, Katy
    Martens, William
    Hilbert, James
    Dekdebrun, Jeanne
    Dilek, Nuran
    Zizzi, Christine
    Johnson, Nicholas
    Puwanant, Araya
    Tawil, Rabi
    Schifitto, Giovanni
    Beck, Christopher A.
    Richeson, J. Franklin
    Zareba, Wojciech
    Thornton, Charles
    McDermott, Michael P.
    Moxley, Richard
    NEUROLOGY, 2021, 96 (02) : E228 - E240
  • [10] Metoclopramide for the treatment of Tourette syndrome: A randomized, double-blind, placebo-controlled trial
    Nicolson, R
    Smith, J
    Castellanos, FX
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S277 - S277
12345